Erratum: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (The Lancet (2013) 381(9869) (805–816)(S0140673612619631)(10.1016/S0140-6736(12)61963-1));Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

The Lancet

Volumn 381, Issue 9869, 2013, Pages 805-816

  Davies, Christina ^a   Pan, Hongchao ^a   Godwin, Jon ^b   Gray, Richard ^a   Arriagada, Rodrigo ^c   Raina, Vinod ^d   Abraham, Mirta ^e   Medeiros Alencar, Victor Hugo ^f   Badran, Atef ^g   Bonfill, Xavier ^h   Bradbury, Joan ⁱ   Clarke, Michael ^j   Collins, Rory ^a   Davis, Susan R ⁱ   Delmestri, Antonella ^a   Forbes, John F ^k   Haddad, Peiman ^l   Hou, Ming Feng ^m   Inbar, Moshe ⁿ   Khaled, Hussein ^g   Kielanowska, Joanna ^o   Kwan, Wing Hong ^p   Mathew, Beela S ^q   Mittra, Indraneel ^r   Müller, Bettina ^s   Nicolucci, Antonio ^t   Peralta, Octavio ^s   Pernas, Fany ^u   Petruzelka, Lubos ^v   Pienkowski, Tadeusz ^w   Radhika, Ramachandran ^x   Rajan, Balakrishnan ^y   Rubach, Maryna T ^o   Tort, Sera ^h   Urrútia, Gerard ^h   Valentini, Miriam ^t   Wang, Yaochen ^a   Peto, Richard ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUTE ROTARY CANCER HOSPITAL   (India)

^e Instituto Cardiovascular Rosario (ICR)   (Argentina)

^f Instituto do Cancer do Ceara   (Brazil)

^g CAIRO UNIVERSITY   (Egypt)

^h CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

ⁱ MONASH UNIVERSITY   (Australia)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k UNIVERSITY OF NEWCASTLE   (Australia)

^l TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^m KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁿ TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^o INSTITUTE OF ONCOLOGY   (Poland)

^p Comprehensive Oncology Centre ^*  (Hong Kong)

^q REGIONAL CANCER CENTRE   (India)

^r TATA MEMORIAL HOSPITAL   (India)

^s Chilean Cooperative Group for Oncologic Research (GOCCHI)   (Chile)

^t Consorzio Mario Negri Sud ^*  (Italy)

^u Instituto de Inmunología Clínica y Experimental de Rosario   (Argentina)

^v CHARLES UNIVERSITY   (Czech Republic)

^w European Health Centre Otwock (ECZO)   (Poland)

^x CANCER INSTITUTE WIA   (India)

^y ROYAL HOSPITAL   (Oman)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84874745627     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60252-4     Document Type: Erratum

References (24)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
3. Swain SM. Tamoxifen: the long and short of it. J Natl Cancer Inst 1996; 88: 1510-12.
4. Peto R. Five years of tamoxifen-or more? J Natl Cancer Inst 1996; 88: 1791-93.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-62.
6. Fisher B, Dignam J, Bryant J, et al. The worth of 5 versus more than 5 years of tamoxifen therapy for breast cancer patients with negative nodes and estrogen-receptor positive tumors: an update of NSABP B-14. J Natl Cancer Inst 1996; 88: 1529-43.
7. Tormey DC, Gray R, Falkson HC, for the Eastern Co-operative Oncology Group. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996; 88: 1828-33.
8. Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer 1996; 74: 297-99.
9. US National Institutes of Health. National Cancer Institute Clinical Announcement: adjuvant therapy of breast cancer-tamoxifen update. Bethesda, MD: National Institutes of Health, 1995.
10. US National Institutes of Health. NIH consensus statement. Adjuvant therapy for breast cancer: http://consensus.nih.gov/2000/ 2000AdjuvantTherapyBreastCancer114html.htm (accessed Oct 10, 2012).
11. Gray R, Davies C, Perry P. Tamoxifen for early breast cancer: better late than never. Ann Oncol 2000; 11: 505-07.
12. Earl H, Gray R, Kerr D, Lee M. The optimal duration of tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. Clin Oncol (R Coll Radiol) 1997; 9: 141-43.
13. Gray RG, Rea DW, Handley K, et al. ATTom: randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6, 934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-preliminary results. Proc Am J Clin Oncol 2008; 26 (suppl 10): abstr 513.
14. Davies C, McGale P, Peto R. Variation in use of adjuvant tamoxifen. Lancet 1998; 351: 1487-88.
15. WHO. International statistical classification of diseases and health-related problems, tenth revision. Geneva: World Health Organization, 1992.
16. Li CI, Kathleen E, Malone E, Daling Jr. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002; 11: 601-07.
17. Goss PE. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol 2006; 33 (suppl 7): S8-S12.
18. Early Breast Cancer Trialists' Collaborative Group. Introduction and methods. In: Treatment of early breast cancer: worldwide evidence, 1985-1990. Oxford: Oxford University Press, 1990. http://www.ctsu. ox.ac.uk/research/meta- trials/ebctcg/original-methods-for-ebctcg-meta-analyses (accessed Oct 10, 2012).
19. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in post-menopausal women. Ann Intern Med 1991; 115: 860-64.
20. McDonald CC, Stewart HJ, for the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. BMJ 1991; 303: 435-37.
21. Guetta V, Lush RM, Figg WD, et al. Effects of the antioestrogen tamoxifen on low density lipoprotein concentrations and oxidation in post-menopausal women. Am J Cardiol 1995; 76: 1072-73.
22. Heart Protection Study Collaborative Group. Effects on 11 year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20, 536 high-risk individuals. Lancet 2011; 378: 2013-20.
23. US Food and Drug Administration. Nolvadex (tamoxifen citrate). http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm154510.htm (accessed Oct 10, 2012).
24. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-18.